Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Pembrolizumab in Patients with MSI-H Advanced Endometrial Cancer from the KEYNOTE-158 Study


29 Sep 2019


Poster Display session 2


David Omalley


Annals of Oncology (2019) 30 (suppl_5): v403-v434. 10.1093/annonc/mdz250


D. Omalley1, A. Marabelle2, A. De Jesus-Acosta3, S.A. Piha-Paul4, A. Arkhipov5, F. Longo6, D. Motola-Kuba7, R. Shapira-Frommer8, R. Geva9, B.J. Rimel10, J.A. Lopez-Martin11, A.R. Hansen12, J.M. Mehnert13, X. Chen14, F. Jin14, K. Norwood14, P.A. Ott15

Author affiliations

  • 1 Ob/gyn, The Ohio State University James Cancer Hospital, 43210 - Columbus/US
  • 2 Drug Development Department, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 3 Medical Oncology, Johns Hopkins Hospital, 21231 - Baltimore/US
  • 4 Department Of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, 77030 - Houston/US
  • 5 Chemotherapy And Radiotherapy Department, Federal State Autonomous Institution “Treatment and Rehabilitation Center” of the Ministry of Health of Russian Federation, 125367 - Moscow/RU
  • 6 Medical Oncology, Hospital Universitario Ramon y Cajal, 28034 - Madrid/ES
  • 7 Clinical Investigation, COMOP A.C., 06100 - Mexico City/MX
  • 8 Oncology, Chaim Sheba Medical Center, 52621 - Ramat Gan/IL
  • 9 Division Of Oncology, Tel Aviv Sourasky Medical Center-(Ichilov), 64239 - Tel Aviv/IL
  • 10 Gynecology-oncology, Cedars-Sinai Medical Center, 90048 - Los Angeles/US
  • 11 Medical Oncology, 12 de Octubre University Hospital & Research Institute (i+12), 28041 - Madrid/ES
  • 12 Medical Oncology And Hematology, Princess Margaret Cancer Center, M5G 2M9 - Toronto/CA
  • 13 Medical Oncology, Rutgers Cancer Institute of New Jersey, 08903 - New Brunswick/US
  • 14 Mrl, Merck & Co., Inc., 07033 - Kenilworth/US
  • 15 Medical Oncology, Dana Farber Cancer Institute, 02215 - Boston/US



Pembrolizumab (pembro) provides durable responses in patients (pts) with MSI-H cancers and is approved in the US/Japan for the treatment of MSI-H advanced solid tumors. MSI-H is expressed in ∼25% of endometrial cancers. An analysis of pts with MSI-H advanced endometrial cancer enrolled in cohorts D (advanced endometrial cancer) and K (pan-tumor MSI-H) of the phase 2 KEYNOTE-158 basket study (NCT02628067) is presented.


Eligible pts had advanced endometrial cancer; progression on or intolerance to ≥ 1 line of standard therapy; measurable disease per RECIST v1.1; ECOG PS ≤ 1; and an MSI-H tumor sample determined retrospectively by centrally performed PCR (cohort D) or prospectively by locally performed IHC or PCR (cohort K). Pts received pembro 200 mg Q3W for up to 2 y or until PD or unacceptable toxicity. Tumor imaging was performed every 9 wk for the first 12 mo, and every 12 wk thereafter. Response was assessed per RECIST v1.1 by independent central radiologic review. The primary endpoint was ORR; secondary endpoints included DOR, PFS, OS and safety. Data cutoff was Dec 6, 2018.


49 pts with MSI-H advanced endometrial cancer were enrolled in cohorts D (n = 11) and K (n = 38). Median age was 65 (range, 42-86) y; 51% had ECOG PS 1; 49% had received ≥2 lines of prior therapy; and histology was endometrioid in 53%, adenocarcinoma in 43%, clear cell in 2% and mucinous in 2% of pts. Median follow-up duration was 24 (range, 0.5-34) mo. ORR was 57% (95% CI, 42%-71%), with 8 (16%) CR and 20 (41%) PR. 8 pts (16%) had SD, and the DCR was 73%. Median DOR was not reached (NR; range, 3-27+ mo); 26 (93%) of the 28 responses were ongoing after ≥9 mo follow-up. Reduction in tumor size was observed in 37 (79%) of the 47 pts with ≥1 evaluable assessment. Median PFS was 26 (95% CI, 5-NR) mo. The 12-mo OS rate was 73%, with median OS not reached (95% CI, 27 mo-NR). Treatment-related AEs occurred in 39 (80%) pts; the most common events were fatigue (26%) and diarrhea (24%). 16% of pts had treatment-related grade 3-4 AEs; there were no grade 5 AEs.


Pembro is associated with robust, durable antitumor activity with promising survival benefit and manageable safety in pts with heavily pretreated MSI-H advanced endometrial cancer.

Clinical trial identification


Editorial acknowledgement

Christine McCrary Sisk, funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Legal entity responsible for the study

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.


Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.


D. O\'Malley: Honoraria (self): AstraZeneca, Clovis, Tesaro, Immunogen, Ambry Genetics, Janssen/J&J, AbbVie, Amgen, Regeneron, Genentech/Roche, Novocure, GOG Foundation; Advisory / Consultancy: AstraZeneca, Clovis, Tesaro, Immunogen, Ambry Genetics, AbbVie, Amgen, Genentech/Roche, Novocure, Agenus; Research grant / Funding (institution): AstraZeneca, Clovis, Tesaro, Immunogen, Janssen/J&J, AbbVie, Regeneron, Amgen, Novocure, Genentech/Roche, VentiRx, Array Biopharma, EMD Serono, Ergomed, Ajinomoto Inc., Ludwig Cancer Research, Stemcentrx, Inc, Cerulean Pharma, GOG Group; Travel / Accommodation / Expenses: Agenus; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Bristol-Myers Squibb Co, Serono Inc, Tracon Pharmaceuticals Yale University, New Mexico Cancer Care Alliance, INC Research, Inc, inVentiv Health Clinical, Iovance Biotherapeutics, Inc, PRA Intl, Agenus. A. Marabelle: Advisory / Consultancy, Principal Investigator of Clinical Trials: Roche/Genentech, BMS, Merck (MSD), Pfizer, Lytix pharma, Eisai, AstraZeneca/Medimmune, Tesaro, Chugai; Advisory / Consultancy, Principal Investigator of Academic Trials: INCa, Ligue contre le Cancer, BMS, Unicancer, Transgene, Leon Berard Cancer Centre, BMS, Gustave Roussy, Boehringer Ingelheim; Advisory / Consultancy, Sub-Investigator of Clinical Trials: Aduro Biotech, Agios Pharmaceuticals, Amgen, Argen-X Bvba, Arno Therapeutics, Astex Pharmaceuticals, AstraZeneca, Aveo, Bayer Healthcare Ag, Bbb Technologies Bv, Beigene, Bioalliance Pharma, Biontech Ag, Blueprint Medicines, Boehringer Ingelheim, Bristol; Research grant / Funding (self): AstraZeneca, BMS, Boehringer Ingelheim, Janssen Cilag, Merck, Novartis, Pfizer, Roche, Sanofi; Research grant / Funding (institution), (drug supply): AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Johnson & Johnson, Lilly, Medimmune, Merck, NH TherAGuiX, Pfizer, Roche; Advisory / Consultancy, Member of Clinical Trial Scientific Committee: GSK, AstraZeneca; Advisory / Consultancy, Member of Data Safety and Monitoring Board: Oncovir, Inc.; Honoraria (self), Scientific Advisory Boards: Innate Pharma, Merck Serono, eTheRNA, Lytix pharma, Kyowa Kirin Pharma, Bayer, Novartis, BMS, Symphogen, Genmab, Amgen, Biothera, Nektar, GSK, Oncovir, Pfizer, Seattle Genetics, Flexus Bio, Roche/Genentech, OSE immunotherapeutics, Transgene, Gritstone; Speaker Bureau / Expert testimony: Roche/Genentech, BMS, Merck (MSD), Merck Serono, AstraZeneca/Medimmune, Amgen, Sanofi; Advisory / Consultancy, Scientific & Medical Consulting: Roche, Pierre Fabre, Onxeo, Eisai, Bayer, Genticel, Rigontec, Daichii Sankyo, Imaxio, Sanofi, BioNTech, Corvus, GLG, Deerfield, Guidepoint Global, Edimark, System Analytics, imCheck, Sotio, Bioncotech, Molecular Partners, Pillar Partners, Boehringer Ingel; Travel / Accommodation / Expenses: AstraZeneca, BMS, Merck (MSD), Roche; Shareholder / Stockholder / Stock options, Co-founder and Share Holder: Pegascy SAS (Gustave Roussy Spin Off for Drug Repositioning); Licensing / Royalties, Patent Issued (not licensed yet): “Humanized and Chimeric Monoclonal Antibodies to CD81”, Stanford Office of Technology Licensing, 3000 El Camino Real, Bldg. 5, Suite 300, Palo Alto, CA 94306-2100. U.S. Application Serial No. 62/351,054.; Research grant / Funding (institution): Merus, BMS, Boehringer Ingelheim, Transgene, Fondation MSD Avenir; Officer / Board of Directors, Supervisory Board Member: Gustave Roussy Foundation; Advisory / Consultancy, Member of the Steering Committee of the Immuno-Oncology Task Force: Unicancer; Advisory / Consultancy, Sub-investigator of Clinical Trials: Bristol-Myers Squibb, Ca, Celgene Corporation, Chugai Pharmaceutical Co., Clovis Oncology, Daiichi Sankyo, Debiopharm S.A., Eisai, Exelixis, Forma, Gamamabs, Genentech, Inc., Gilead Sciences, Inc, GlaxoSmithKline, Glenmark Pharmaceuticals, H3 Biomedicine; Advisory / Consultancy, Sub-investigator of Clinical Trials: Hoffmann La Roche Ag, Incyte Corporation, Innate Pharma, Iris Servier, Janssen, Kura Oncology, Kyowa Kirin Pharm, Lilly, Loxo Oncology, Lytix Biopharma As, Medimmune, Menarini Ricerche, Merck Sharp & Dohme Chibret, Merrimack Pharmaceuticals, Merus; Advisory / Consultancy, Sub-investigator of Clinical Trials: Millennium Pharmaceuticals, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Octimet Oncology Nv, Oncoethix, Oncomed, Oncopeptides, Onyx Therapeutics, Orion Pharma, Oryzon Genomics, Pfizer, Pharma Mar, Pierre Fabre, Rigontec Gmbh, Roche; Advisory / Consultancy, Sub-investigator of Clinical Trials: Sanofi Aventis, Sierra Oncology, Taiho Pharma, Tesaro, Inc, Tioma Therapeutics, Inc., Xencor; Honoraria (self), Scientific Advisory Boards: Merck (MSD), Cerenis, Innate pharma, Protagen, Partner Therapeutics, Servier, Sanofi, Pierre Fabre, Molecular Partners, Innate Pharma. A. De Jesus-Acosta: Advisory / Consultancy: Merck & Co., Inc.; Research grant / Funding (self): Merck & Co., Inc., AZ; Research grant / Funding (institution): Merck & Co., Inc. S.A. Piha-Paul: Research grant / Funding (institution): AbbVie, Inc.; Aminex Therapeutics; BioMarin Pharmaceutical, Inc; Boehringer Ingelheim; Bristol Myers Squib; Cerulean Pharma Inc.; Chugai Pharmaceutical Co., Ltd; Curis, Inc.; Five Prime Therapeutics; Flex Bio, Inc.; Genmab A/S; GlaxoSmithKline; Research grant / Funding (institution): Helix BioPharma Corp.; Incyte Corp.; Jacobio Pharmaceuticals Co., Ltd.; Medimmune, LLC.; Medivation, Inc.; Merck Sharp and Dohme Corp.; NewLink Genetics Corporation/Blue Link Pharmaceuticals; Novartis Pharmaceuticals; Pieris Pharmaceuticals, Inc.; Pfizer; Research grant / Funding (institution): Principia Biopharma, Inc.; Puma Biotechnology, Inc.; Seattle Genetics; Taiho Oncology; Tesaro, Inc.; TransThera Bio; XuanZhu Biopharma. A. Arkhipov: Research grant / Funding (institution): MSD. F. Longo: Research grant / Funding (institution): MSD. D. Motola-Kuba: Speaker Bureau / Expert testimony: Pfizer, MSD, Eli Lilly, AstraZeneca, Roche, BMS, Asopharma; Research grant / Funding (institution): MSD. R. Shapira-Frommer: Honoraria (self): MSD, BMS, Roche, Novartis, Medison; Advisory / Consultancy: MSD, Clovis oncology; Research grant / Funding (institution): MSD. R. Geva: Speaker Bureau / Expert testimony, Lecture: MSD, Novartis, Roche, Janssen, Takeda, Pfizer; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses, Lecture & Travel: BMS, Medison, Merck; Research grant / Funding (institution): MSD. B.J. Rimel: Advisory / Consultancy: Tesaro, Clovis, AstraZeneca, Genentech, Deep 6 AI; Research grant / Funding (institution): Merck. J.A. Lopez-Martin: Advisory / Consultancy: MSD, BMS, Roche, Pierre-Fabre, Celgene, Amgen, Novartis, Lilly, PharmaMar, Chobani; Research grant / Funding (institution): MSD, BMS, Roche, Novartis, PharmaMar, Lilly; Travel / Accommodation / Expenses: MSD, Roche, BMS, Lilly, PharmaMar; Shareholder / Stockholder / Stock options: PharmaMar. A.R. Hansen: Advisory / Consultancy, Research grant / Funding (self): Genentech/Roche, Merck, GSK, Bristol-Myers Squibb, Novartis, Boston Biomedical, Boehringer-Ingelheim, AstraZeneca, Medimmune; Research grant / Funding (institution): Merck. J.M. Mehnert: Advisory / Consultancy: Merck, Boehringer Ingelheim, Array Biopharma, Amgen; Research grant / Funding (institution): Merck, Incyte, Macrogenics, Bristol-Myers Squibb; Travel / Accommodation / Expenses: Array Biopharma, Bristol-Myers Squibb. X. Chen: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck & Co., Inc. F. Jin: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck & Co., Inc. K. Norwood: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck & Co., Inc. P.A. Ott: Honoraria (self): Alexion, Array, Bristol-Myers Squibb, Celldex, CytomX, Genentech, Merck, Neon Therapeutics, Novartis, Pfizer, TRM Oncology; Advisory / Consultancy: Alexion, Array, Bristol-Myers Squibb, Celldex, CytomX, Genentech, Merck, Neon Therapeutics, Novartis, Pfizer, TRM Oncology; Research grant / Funding (institution): Armo Biosciences, AstraZeneca/MedImmune, Bristol-Myers Squibb, Celldex, CytomX, Genentech, Merck, Neon Therapeutics, Novartis, Pfizer.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings